• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒 2 的实验室诊断。

Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2.

机构信息

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, NSW, Australia.

Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia.

出版信息

Pathology. 2020 Dec;52(7):745-753. doi: 10.1016/j.pathol.2020.09.011. Epub 2020 Oct 8.

DOI:10.1016/j.pathol.2020.09.011
PMID:33131799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7543760/
Abstract

The first laboratory confirmed case of Coronavirus disease 2019 (COVID-19) in Australia was in Victoria on 25 January 2020 in a man returning from Wuhan city, Hubei province, the People's Republic of China. This was followed by three cases in New South Wales the following day. The Australian Government activated the Australian Health Sector Emergency Response Plan for Novel Coronavirus on 27 February 2020 in anticipation of a pandemic. Subsequently, the World Health Organization declared COVID-19 to be a Public Health Emergency of International Concern followed by a pandemic on 30 January 2020 and 11 March 2020, respectively. Laboratory testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, is key in identifying infected persons to guide timely public health actions of contact tracing and patient isolation to limit transmission of infection. This article aims to provide a comprehensive overview of current laboratory diagnostic methods for SARS-CoV-2, including nucleic acid testing, serology, rapid antigen detection and antibody tests, virus isolation and whole genome sequencing. The relative advantages and disadvantages of the different diagnostic tests are presented, as well as their value in different clinical, infection control and public health contexts. We also describe the challenges in the provision of SARS-CoV-2 diagnostics in Australia, a country with a relatively low COVID-19 incidence in the first pandemic wave but in which prevalence could rapidly change.

摘要

澳大利亚首例 2019 年冠状病毒病(COVID-19)实验室确诊病例于 2020 年 1 月 25 日在维多利亚州出现,患者为一名从中国湖北省武汉市返回的男子。次日,新南威尔士州又报告了三例病例。澳大利亚政府于 2020 年 2 月 27 日启动了澳大利亚卫生部门新发冠状病毒应急计划,以应对大流行。随后,世界卫生组织于 2020 年 1 月 30 日和 3 月 11 日分别宣布 COVID-19为国际关注的突发公共卫生事件和大流行。针对导致 COVID-19 的严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的实验室检测是识别感染者的关键,以便及时采取公共卫生措施进行接触者追踪和患者隔离,以限制感染传播。本文旨在全面概述 SARS-CoV-2 的当前实验室诊断方法,包括核酸检测、血清学检测、快速抗原检测和抗体检测、病毒分离和全基因组测序。介绍了不同诊断检测方法的相对优缺点,以及它们在不同临床、感染控制和公共卫生背景下的价值。我们还描述了澳大利亚在提供 SARS-CoV-2 诊断方面面临的挑战,澳大利亚在第一波大流行期间 COVID-19 发病率相对较低,但流行率可能会迅速变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4780/7543760/dac7cde24d3c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4780/7543760/dac7cde24d3c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4780/7543760/dac7cde24d3c/gr1_lrg.jpg

相似文献

1
Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2.严重急性呼吸综合征冠状病毒 2 的实验室诊断。
Pathology. 2020 Dec;52(7):745-753. doi: 10.1016/j.pathol.2020.09.011. Epub 2020 Oct 8.
2
Laboratory diagnosis of COVID-19 in China: A review of challenging cases and analysis.中国 COVID-19 的实验室诊断:疑难病例回顾与分析。
J Microbiol Immunol Infect. 2021 Feb;54(1):17-26. doi: 10.1016/j.jmii.2020.10.004. Epub 2020 Oct 17.
3
Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus Research & Diagnostic Laboratories.印度针对 SARS-CoV-2 检测的实验室准备:利用病毒研究和诊断实验室网络。
Indian J Med Res. 2020;151(2 & 3):216-225. doi: 10.4103/ijmr.IJMR_594_20.
4
Current Status of Diagnostic Testing for SARS-CoV-2 Infection and Future Developments: A Review.SARS-CoV-2 感染诊断检测的现状及未来发展:综述
Med Sci Monit. 2020 Dec 17;26:e928552. doi: 10.12659/MSM.928552.
5
Bondi and beyond. Lessons from three waves of COVID-19 from 2020.邦迪及以外地区:2020 年三波 COVID-19 的经验教训。
Public Health Res Pract. 2021 Sep 8;31(3):3132112. doi: 10.17061/phrp3132112.
6
Over 90% of clinical swabs used for SARS-CoV-2 diagnostics contain sufficient nucleic acid concentrations.超过 90%用于 SARS-CoV-2 诊断的临床拭子含有足够的核酸浓度。
J Med Virol. 2021 May;93(5):2848-2856. doi: 10.1002/jmv.26706. Epub 2021 Feb 16.
7
The Potential Transmission of SARS-CoV-2 from Patients with Negative RT-PCR Swab Tests to Others: Two Related Clusters of COVID-19 Outbreak.从 RT-PCR 咽拭子检测阴性的患者向他人传播 SARS-CoV-2 的可能性:两起新冠肺炎暴发的聚集性疫情。
Jpn J Infect Dis. 2020 Nov 24;73(6):399-403. doi: 10.7883/yoken.JJID.2020.165. Epub 2020 May 29.
8
Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes.用于诊断和研究目的的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的病毒分离。
Pathology. 2020 Dec;52(7):760-763. doi: 10.1016/j.pathol.2020.09.012. Epub 2020 Oct 8.
9
Laboratory testing for the diagnosis of COVID-19.用于 COVID-19 诊断的实验室检测。
Biochem Biophys Res Commun. 2021 Jan 29;538:226-230. doi: 10.1016/j.bbrc.2020.10.069. Epub 2020 Oct 28.
10
Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art.诊断 COVID-19 以控制疫情:现状综述。
Biosens Bioelectron. 2021 Feb 15;174:112830. doi: 10.1016/j.bios.2020.112830. Epub 2020 Nov 27.

引用本文的文献

1
First Results of an External Quality Assessment (EQA) Scheme for Molecular, Serological and Antigenic Diagnostic Test for SARS-CoV-2 Detection in Lombardy Region (Northern Italy), 2020-2022.2020 - 2022年意大利北部伦巴第地区针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)检测的分子、血清学和抗原诊断测试外部质量评估(EQA)计划的初步结果
Diagnostics (Basel). 2022 Jun 16;12(6):1483. doi: 10.3390/diagnostics12061483.
2
Frontliners on the Move: A Quantitative Analysis of the Prevalence of COVID-19 Reinfection Among Healthcare Workers.前线人员动态:医护人员中新冠病毒再感染率的定量分析
Cureus. 2022 May 1;14(5):e24652. doi: 10.7759/cureus.24652. eCollection 2022 May.
3

本文引用的文献

1
Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.利用血清学调查估算 SARS-CoV-2 血清流行率和不确定的流行病学参数。
Elife. 2021 Mar 5;10:e64206. doi: 10.7554/eLife.64206.
2
The Antibody Response to SARS-CoV-2 Infection.对新型冠状病毒感染的抗体反应。
Open Forum Infect Dis. 2020 Aug 27;7(9):ofaa387. doi: 10.1093/ofid/ofaa387. eCollection 2020 Sep.
3
Efficient high-throughput SARS-CoV-2 testing to detect asymptomatic carriers.高效高通量 SARS-CoV-2 检测以发现无症状感染者。
Considerations regarding Interpretation of Positive SARS-CoV-2 Molecular Results with Late Cycle Threshold Values.
关于晚期循环阈值下 SARS-CoV-2 分子检测阳性结果解释的注意事项。
J Clin Microbiol. 2022 Sep 21;60(9):e0050122. doi: 10.1128/jcm.00501-22. Epub 2022 Jun 6.
4
Laboratory Diagnosis for SARS-CoV-2 Infection.SARS-CoV-2 感染的实验室诊断。
Infect Dis Clin North Am. 2022 Jun;36(2):327-347. doi: 10.1016/j.idc.2022.02.002.
5
Disease Prevalence Matters: Challenge for SARS-CoV-2 Testing.疾病流行率至关重要:新冠病毒检测面临的挑战。
Antibodies (Basel). 2021 Dec 17;10(4):50. doi: 10.3390/antib10040050.
6
Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population.儿科人群中抗SARS-CoV-2抗体的长期持久性
Pathogens. 2021 Jun 4;10(6):700. doi: 10.3390/pathogens10060700.
7
Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2.基于 Luminex 的 2019 年冠状病毒病悬浮免疫分析(COVID-19 SIA)对检测 SARS-CoV-2 抗体的诊断潜力。
Viruses. 2021 May 26;13(6):993. doi: 10.3390/v13060993.
8
Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection.用于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)/COVID-19 检测的工具和技术。
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00228-20. Print 2021 Jun 16.
9
Evaluation of 32 rapid tests for detection of antibodies against SARS-CoV-2.评估 32 种快速检测 SARS-CoV-2 抗体的方法。
Clin Chim Acta. 2021 Aug;519:133-139. doi: 10.1016/j.cca.2021.04.016. Epub 2021 Apr 27.
10
Neuropathology of COVID-19 (neuro-COVID): clinicopathological update.新型冠状病毒肺炎的神经病理学(神经型新冠):临床病理进展
Free Neuropathol. 2021 Jan 18;2:2. doi: 10.17879/freeneuropathology-2021-2993.
Sci Adv. 2020 Sep 11;6(37). doi: 10.1126/sciadv.abc5961. Print 2020 Sep.
4
Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis.唾液作为新冠病毒诊断检测的候选样本:一项荟萃分析
Front Med (Lausanne). 2020 Aug 4;7:465. doi: 10.3389/fmed.2020.00465. eCollection 2020.
5
Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved by Emergency-Use-Authorization in Korea.韩国紧急使用授权批准的四种用于严重急性呼吸综合征冠状病毒2实时逆转录聚合酶链反应的商用试剂盒评估
Front Med (Lausanne). 2020 Aug 13;7:521. doi: 10.3389/fmed.2020.00521. eCollection 2020.
6
A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients.增强型唾液样本与鼻咽拭子样本检测 SARS-CoV-2 比较:对有症状患者的研究。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01946-20.
7
Tracking the COVID-19 pandemic in Australia using genomics.利用基因组学追踪澳大利亚的 COVID-19 疫情。
Nat Commun. 2020 Sep 1;11(1):4376. doi: 10.1038/s41467-020-18314-x.
8
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的唾液或鼻咽拭子样本
N Engl J Med. 2020 Sep 24;383(13):1283-1286. doi: 10.1056/NEJMc2016359. Epub 2020 Aug 28.
9
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.评估 SARS-CoV-2 血清学检测方法显示出一系列的检测性能。
Nat Biotechnol. 2020 Oct;38(10):1174-1183. doi: 10.1038/s41587-020-0659-0. Epub 2020 Aug 27.
10
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study.SARS-CoV-2 和 SARS-CoV 的比较嗜性、复制动力学和细胞损伤特征分析及其对 COVID-19 临床表现、传染性和实验室研究的影响:一项观察性研究。
Lancet Microbe. 2020 May;1(1):e14-e23. doi: 10.1016/S2666-5247(20)30004-5. Epub 2020 Apr 21.